UNSPSC 51312106: Lodoxamide ethyl

This classification denotes a mast cell stabilizer with the molecular formula C15H14ClN3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TQY1B8145B, chemically known as acetic acid, 2,2'-((2-chloro-5-cyano-1,3-phenylene)diimino)-, bis 2-oxo-, diethyl ester, but more generally known as lodoxamide ethyl, which bears US NIH Compound Identifier 40915. European Medicines Agency schedules lodoxamide ethyl or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08553MIG.

Most nations, for tariff purposes, schedule lodoxamide ethyl under HS 29269095. SMILES: CCOC(=O)C(=O)NC1CC(CC(C1CL)NC(=O)C(=O)OCC)C#N.

UNSPSC 51312106 Lodoxamide ethyl, a Commodity code, does not align with the state and local procurement activity currently tagged under it. The three recent opportunities in the record—naloxone and drug-deactivation-system procurement from Seminole County, Florida; a Texas HHS Commission RFI on direct-to-manufacturer prescription programs; and a Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products—are all pharmaceutical supply-chain and public-health procurement, but none specifically solicit lodoxamide ethyl, a mast-cell stabilizer used in ophthalmology. The code shows little activity relevant to the commodity's nominal scope, and the opportunities posted instead reflect broader state and local buying patterns in drug procurement, vendor contracting through cooperative purchasing vehicles, and pharmacy-benefit program management.

The issuing-body mix reflects state departments, regional multi-state purchasing consortia, and county health agencies. MMCAP (Minnesota Department of Administration on behalf of multiple states including Oregon) and the Texas Health and Human Services Commission represent state-level pharmaceutical procurement infrastructure; Seminole County's IFB for naloxone reflects county-level public-health purchasing. No repeat buyers under the specific lodoxamide ethyl code appear in the recent record. The geographic spread covers Florida, Texas, and Minnesota/Oregon, but the code itself reports no active market for the commodity as currently classified. The Seminole County naloxone procurement (IFB 60459723LAS, due July 26, 2023) and the MMCAP generic pharmaceuticals RFP (S1070000015802, due March 26, 2026) show state and local demand for pharmaceutical products through competitive bidding and cooperative purchasing; the Texas RFI (HHS0017013, posted April 3, 2026) signals emerging interest in direct-to-manufacturer pharmacy contracting. A procurement professional evaluating lodoxamile ethyl should monitor whether future opportunities are recoded to a broader pharmaceutical or ophthalmic-product family that better captures actual buying activity, or pursue opportunities under the Family or Class codes that encompass the product category.